Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1CNS 1Breast 1

Conditions

Pathologic Processes 1Nervous System Neoplasms 1Nervous System Diseases 1Neoplastic Processes 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Glioma 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Breast Neoplasms 1Brain Neoplasms 1Brain Diseases 1

Interventions

Pemetrexed 7Carboplatin 7Cisplatin 5pembrolizumab 4durvalumab 4osimertinib 3Paclitaxel 3selpercatinib 2pralsetinib 2cobimetinib 2Radiosurgery 2Erlotinib Hydrochloride 2130-nm albumin-bound paclitaxel 2trametinib 1taletrectinib 1sotorasib 1repotrectinib 1patritumab 1napabucasin 1glutathione pegylated liposomal doxorubicin 1ficlatuzumab 1exemestane 1enzalutamide 1entinostat 1dabrafenib 1ceralasertib 1cemiplimab 1camrelizumab 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × glutathione pegylated liposomal doxorubicin × Thoracic × Clear all
NCT01386580 2015-01-22

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

BBB-Therapeutics B.V.

Phase 1/2 Completed
84 enrolled
BreastCNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases, Glioma, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Nervous System Diseases, Nervous System Neoplasms, Pathologic Processes, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡